Skip to main content
Clinical Trials/NCT03185572
NCT03185572
Unknown
Not Applicable

The Prevalence, Disease Course, Prognosis and Interaction of Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension

Chinese Academy of Medical Sciences, Fuwai Hospital1 site in 1 country1,708 target enrollmentJune 15, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COPD
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Enrollment
1708
Locations
1
Primary Endpoint
COPD exacerbations
Last Updated
8 years ago

Overview

Brief Summary

Pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD). It is reported that over half of COPD patients develop pulmonary hypertension. COPD and pulmonary hypertension may have pathological or genetics interactions so that patients having both disorders tend to have poor prognosis. Echocardiography is widely used to detect pulmonary hypertension, but it's not accurate enough. Therefore, high-quality data reflecting the prevalence, disease course and outcome of pulmonary hypertension in COPD is very limited in China. The aim of the study is to detect pulmonary hypertension with right heart catheterization, describe its outcome in Chinese COPD patients and explore the underlying interaction mechanism.

Registry
clinicaltrials.gov
Start Date
June 15, 2017
End Date
December 31, 2020
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Responsible Party
Principal Investigator
Principal Investigator

Jianguo He

Chief of Pulmonary Vascular Disease Center

Chinese Academy of Medical Sciences, Fuwai Hospital

Eligibility Criteria

Inclusion Criteria

  • Stable chronic obstructive pulmonary disease (COPD) patients

Exclusion Criteria

  • Patients with other serious respiratory diseases
  • Patients with pulmonary hypertension other than group 3
  • Patients with right heart hypertrophy or dysfunction not caused by chronic obstructive pulmonary diseases
  • Patients with limited life expectancy
  • Patients with history of tracheal intubation or stoke, acute coronary syndrome in 6 months
  • Psychopath or addict

Outcomes

Primary Outcomes

COPD exacerbations

Time Frame: 3 years

total hospitalizations times due to COPD exacerbations

Secondary Outcomes

  • modified British medical research council (mMRC) score(3 years)
  • transplant-free survival rate(3 years)
  • COPD Assessment Test (CAT) score(3 years)
  • 6 minutes walk distance(3 years)

Study Sites (1)

Loading locations...

Similar Trials